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Abstract
Background: Polycystic Kidney Disease is characterized by the formation of large fluid-filled cysts that eventually
destroy the renal parenchyma leading to end-stage renal failure. Although remarkable progress has been made in
understanding the pathologic mechanism of the disease, the precise orchestration of the early events leading to
cyst formation is still unclear. Abnormal cellular proliferation was traditionally considered to be one of the primary
irregularities leading to cyst initiation and growth. Consequently, many therapeutic interventions have focused on
targeting this abnormal proliferation, and some have even progressed to clinical trials. However, the role of
proliferation in cyst development was primarily examined at stages where cysts are already visible in the kidneys
and therefore at later stages of disease development.
Methods: In this study we focused on the cystic phenotype since birth in an attempt to clarify the temporal
contribution of cellular proliferation in cyst development. Using a PKD2 transgenic rat model (PKD2 (1-703)) of
different ages (0-60 days after birth) we performed gene expression profiling and phenotype analysis by measuring
various kidney parameters.
Results: Phenotype analysis demonstrated that renal cysts appear immediately after birth in the PKD2 transgenic
rat model (PKD2 (1-703)). On the other hand, abnormal proliferation occurs at later stages of the disease as
identified by gene expression profiling. Interestingly, other pathways appear to be deregulated at early stages of
the disease in this PKD model. Specifically, gene expression analysis demonstrated that at day 0 the RAS system is
involved. This is altered at day 6, when Wnt signaling and focal adhesion pathways are affected. However, at and
after 24 days, proliferation, apoptosis, altered ECM signaling and many other factors become involved.
Conclusions: Our data suggest that cystogenesis precedes deregulation of proliferation-related pathways,
suggesting that proliferation abnormalities may contribute in cyst growth rather than cyst formation.
Background
Autosomal Dominant Polycystic Kidney Disease
(ADPKD) is one of the most common inherited mono-
genic disorders in humans, with a prevalence of about
1:1000. It is characterized by the formation of bilateral
fluid-filled cysts that increase in size and destroy the
renal parenchyma, leading to end-stage renal disease
(ESRD). ADPKD can be caused by mutations in either
the PKD1 (~85% of cases) or the PKD2 gene (~15% of
cases), which encode for polycystin-1 (PC-1) and poly-
cystin-2 (PC-2), respectively.
Although all cells in ADPKD patients carry the same
germline mutation, cysts form in only a minority of
nephrons. The disease is thought to act as recessive on
the cellular level, as it has been shown that the somatic
gain of a ‘second hit’ in the allele inherited by the
healthy parent is necessary for cyst formation. Different
groups have identified somatic mutations in the PKD1
or PKD2 gene in the epithelial cells lining the cysts
[1-4]. Second hits in the epithelial cells lining the cysts
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were found to occur either on the normal allele of the
same affected gene or an allele of the other PKD gene,
supporting a trans-heterozygous model of cyst formation
[5,6].
As expected, emphasis was given in understanding the
process of cyst formation and cyst expansion in ADPKD
kidneys. However, research was targeted on the growth
and expansion of isolated cysts rather than on the
mechanism underlying the initial cyst formation at the
site of the tubular epithelial cell. To that end, remark-
able progress has been made. Cysts arise from various
tubular segments and are lined by a single layer of
epithelium. The most important abnormalities of the
tubular epithelium lining the cysts are: [1] disturbance
in the balance between tubular cell proliferation and
apoptosis [7-11], [2] abnormal fluid secretion [7], [3]
alterations of tubular basement membrane constituents
and the associated extracellular matrix [12], [4] altera-
tions of epithelial cell polarity with apical mislocalisation
of key receptors and enzymes [13], and [5] abnormal
ciliary function and/or formation [14,15].
Numerous therapeutic agents were designed to specifi-
cally target those processes. These include vasopressin
receptor antagonists OPC-31260 and tolvaptan [16,17]
which reduce cAMP production, angiotensin-converting
enzyme inhibitors [18,19], mTOR antagonist rapamycin
[20,21], and the cyclin-dependent kinase inhibitor ros-
covitine [22]. Most of the above mentioned therapeutic
approaches have been shown to reduce cyst volume and
delay disease progression in both animal models and
clinical trials but did not eliminate cyst formation.
From all the observed cellular abnormalities in cystic
epithelia, proliferation was considered to be a primary
event in cyst initiation and growth. Multiple genetically
engineered animal models demonstrated the importance
of augmented proliferation on cyst development. Trans-
genic mice overexpressing the proliferation-related
genes c-myc, SV40 T-antigen, T24 ras, EGFR, Erb2,
TGFa and HGF, all developed cystic kidneys. This
strongly incriminates abnormal proliferation as an
underlying mechanism in cyst development. In conjunc-
tion to this, PC-1 and PC-2 are both involved in a con-
fusing plethora of signaling pathways, such as G-protein
signaling, Jak-STAT, Wnt, AP-1, mTOR, MAPK/ERK,
cAMP and others [reviewed in [23]]. In addition to that,
the direct regulation of the cell cycle by PC-1 was iden-
tified, whereby overexpression of PC-1 leads to activa-
tion of the JAK/STAT pathway and induces cell cycle
arrest through a process that requires PC-2 [24].
Furthermore, PC-2 has been directly linked to cell cycle
regulation through direct interaction with Id2 thereby
regulating the p21-cdk2 pathway [25]. In contrast to
that, in a recent publication, we demonstrated that pri-
mary tubular epithelial cells from a 7.5-week old PKD2
mutant (1-703) transgenic rat, display increased prolif-
eration accompanied by alterations in expression of
Cdk2 and p57, but independent of p21 [26].
Most studies to date, have identified factors that regu-
late proliferation at stages where cysts are already visible
in the kidneys of humans and animal models of PKD
and therefore at later stages of disease development. An
unanswered question is whether unrestricted cellular
proliferation is a causative event in cyst initiation in
ADPKD or it is restricted to a specific period during
cyst expansion and growth. Recent reports attempted to
address this issue using inducible animal models of
ADPKD and studied the kinetics of cyst formation. Spe-
cifically, it was demonstrated that PKD1 regulates tubu-
lar morphology in both developing and adult kidney,
but the disease severity is defined by the kidneys’ devel-
opmental status. Early inactivation of PKD1 resulted in
a severe cystic phenotype in the absence of any prolif-
eration difference between wild-type and mutant ani-
mals. Rather than proliferation defects the authors claim
that distorted planar cell polarity may be responsible for
initial cyst formation [27]. Combined, these results sug-
gest that over-proliferation may participate in cyst
growth rather than cyst initiation.
In order to get a better understanding of the role of
proliferation in cyst initiation we utilized a transgenic
rat model that expresses a truncated form of PC-2.
Transgenic and wild type rats at early stages of the dis-
ease (0, 6 and 24 days) were used and their gene expres-
sion profiles were assessed to identify genes that are
differentially expressed at early stages of the cystogenesis
process. Interestingly, we found that proliferation-related
genes are not differentially expressed at the early stages
of disease, but become deregulated later on. More
importantly, pathway analysis has revealed that the cell
cycle or any of the proliferation-related pathways are
not significantly altered at early stages, but instead,
other pathways including the Renin-Angiotensin System
(RAS), Wnt signaling and focal adhesion pathways
appear to be affected at early stages of cystogenesis.
Methods
Animals
PKD2 mutant transgenic Sprague Dawley (SD) rats
[TGR (CMV-hPKD2/1-703)] were used in this study
[abbreviated in this text as PKD2 (1-703)] [28]. Only
male rats were used for the purposes of this manuscript,
to minimise variability between the sexes. Wild type
(WT) SD rats were used as controls. Three WT and
three PKD2 (1-703) rats from each age of 0, 6, 12, 24,
36, 48 and 60 days were sacrificed following standard
procedures and their kidneys excised. Both kidneys were
weighed and then dissected by cross sections in three
parts. The middle parts of the right kidneys were fixed
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in 2% paraformaldehyde (PFA) for 24 h, 1% PFA for
24 h followed by 4% formalin. These parts were then
embedded in paraffin to be used for cyst grading. The
middle part of the left kidney was submerged in 2%
PFA for 24 hours, then submerged in 18% sucrose for 6
hours, frozen in liquid nitrogen and stored at -80°C. All
other parts were frozen immediately in liquid nitrogen
and then stored at -80°C to be later processed for RNA
and protein analysis. All procedures performed on ani-
mals were done in accordance with institutional guide-
lines for animal research and were approved by the
regional council (no. I 06/12).
Biochemical analysis of blood
Blood from all the animals (apart from the animals of 0
days) was collected by retro-orbital bleeding in Li-
heparin-containing microfuge tubes and used to mea-
sure the biochemical parameters. The microfuge tubes
were centrifuged at 3000 g for 15 min at 4°C and the
supernatant plasma was collected. All biochemical para-
meters measured were determined by standard labora-
tory methods on a Hitachi 911 Autoanalyzer (Roche
Diagnostics). Biochemical parameters including urea,
creatinine, cholesterol, triglycerides, glucose, PO4
3-, K+,
Na+, Ca2+ and total protein were determined.
Cyst and fibrosis grading
Cyst grading was performed on hematoxylin-eosin (HE)-
stained sections.
The extent of cyst formation was assessed in Man-
nheim, Germany, using the previously described cyst
grading system shown below [29]:
For the area of the cortex:
Grade 1 occasionally small, medium- sized and large
cysts and sometimes small accumulations of predomi-
nantly small cysts in up to 4 localisations per slide.
Grade 2 few regular distributed small, medium-sized
and large cysts (up to 5 medium-sized cysts per visual
field).
Grade 3 several small, medium-sized and large cysts
(up to 10 medium-sized cysts per visual field).
Grade 4 a great number of small, medium-sized and
large cysts with 1 or more large cysts in nearly any
visual field; at least, occurrence of 3 “network like struc-
tures” consisting of many cysts of different size linked
together.
Grade 5 practically no normal kidney tissue is visible
and histology exhibits only large cysts and “network like
structures” similar to that seen in homozygous Han:
SPRD (cy/cy) rats. Cysts occur even in the outer cortex
area.
Furthermore the following definitions were used:
Small sized cyst: cyst of the size of 1 glomerulus
Medium sized cyst: cyst of the size of 2 glomeruli
Large sized cyst: cyst of the size of more than 2
glomeruli
The analysis of fibrosis on sections of the kidneys was
also performed at Mannheim, Germany. Sections for the
analysis of fibrosis were Azan-stained. Fibrosis score was
assigned according to the following:
For the area of the cortex:
Grade 1 only a few fibroblasts and fibrocytes, diffuse,
occasionally small scars
Grade 2 several fibroblasts and fibrocytes, diffuse, a
few small fibrotic foci
Grade 3 a great number of fibroblasts and fibrocytes,
diffuse, a few small fibrotic foci and up to 3 large fibro-
tic foci
Grade 4 many fibroblasts and fibrocytes, diffuse, and
more than 3 large fibrotic foci getting into contact with
each other
Antibodies
Primary antibodies used include: mouse monoclonal
antibody against c-myc (9E10) (Santa Cruz Biotechnol-
ogy, USA), mouse monoclonal antibody against PCNA
(Santa Cruz Biotechnology, Inc., USA), mouse monoclo-
nal antibody against b-actin (SIGMA, USA), mouse
monoclonal antibody against rat Ki-67 (M7248, Dako,
Germany). Secondary antibodies used were goat anti-
mouse IgG-HRP (Santa Cruz Biotechnology, USA) and
goat biotinylated anti-mouse IgG (BA-9200, Vector
Laboratories, USA).
Total RNA extraction and Real-Time PCR
15-50 mg from the frozen kidney tissues were used to
extract total RNA from the WT and PKD2(1-703) rats
using the RNeasy® Mini (Qiagen, Germany) or Midi
(Qiagen, Germany) kit depending on the weight of the
tissue obtained. Tissues were grinded in 1.5 ml eppen-
dorf tubes using a pestle. Total RNA was extracted
according to the manufacturer’s instructions. The integ-
rity of the RNA was assessed with gel electrophoresis
and the concentration measured spectrophotometrically.
One μg of total RNA from all samples was reverse tran-
scribed simultaneously, with an oligo-dT (dT23VN) pri-
mer, using the ProtoScript™ First Strand cDNA
Synthesis Kit (New England Biolabs, USA), as recom-
mended by the manufacturer. The quantitative Real-
Time PCR (qRT-PCR) amplifications were performed
on the LightCycler® system (Roche Diagnostics and
Applied Sciences) using the LightCycler® FastStart DNA
Master SYBR Green I kit (Roche, Germany) in a reac-
tion volume of 20 μl. Relative quantification analysis
was carried out on the LightCycler® Software 4.1.
The genes whose differential expression was analysed
by quantitative real-time PCR were: c-myc (forward pri-
mer: AGCGACTCTGAAGAAGAACA, reverse primer:
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ACATGGCACCTCTTGAGGAC), PCNA (forward
primer: TGAAGCACCAAATCAAGAGAAA, reverse
primer: TTTGCACAGGAGATCACCAC) and Ki67 (for-
ward primer: TTCAGTGAAGATCTGTCAGGACTAA,
reverse primer: GGAGCACTTTTTCTCCCAAA). Dif-
ferences in starting material were compensated by nor-
malisation to the endogenous reference gene GAPDH
(forward primer: GTATTGGGCGCCTGGTCACC,
reverse primer: CGCTCCTGGAAGATGGTGATGG).
Western blotting
Ten to 50 mg from the frozen kidneys were homo-
genized in Nonidet® P40 (NP40) buffer (1% NP40, 15%
glycerol, 50 mM Tris HCl (pH 7.4), 200 mM NaCl,
5 mM MgCl2 and a cocktail of protease inhibitors
(Roche, Germany). The homogenates were centrifuged
3 × at 12,000 rpm for 10 min at 4°C and the superna-
tants collected. Protein concentrations were determined
by the BCA assay (Pierce, USA) using BSA as a stan-
dard. Protein lysates were diluted in equal volume of
2 × SDS loading buffer and denatured at 50°C for
30 min. Equal amounts of protein were separated by
SDS-PAGE and transferred to a PVDF membrane.
Membranes were blocked with 5% nonfat dry milk in
PBS/0.1%Tween 20 and incubated with the antibodies.
Detection of the proteins was carried out by enhanced
chemiluminescence (ECL) (Amersham, UK) according
to the manufacturer’s instructions.
Immuno-histochemistry
Paraffin sections were deparaffinised, treated with 0.3%
hydrogen peroxide and subjected to microwave treat-
ment for antigen retrieval (20 min, 10 mM citrate buf-
fer, pH 6,0-6,2). After blocking with 2% BSA in 1 × PBS
for 1 h, sections were incubated first with Ki-67 anti-
body and then with the biotinylated secondary antibody,
each for 1 h at room temperature. Incubation with ABC
reagent and colorimetric detection using the Vectastain®
Elite ABC-Peroxidase Kit, DAB Substrate Kit (Vector
Laboratories, USA) was performed according to the
manufacturers’ instructions. The proliferating cells were
counted in 5 visual fields at a 400 × magnification.
RNA preparation and gene expression profiling with
microarrays
The RNA, to be used for the microarrays, was isolated
using Trizol reagent (Invitrogen, USA). The integrity
and size distribution of the RNA was assessed by the
Agilent Bioanalyzer 2100 (Agilent Technologies, USA),
and its concentration measured spectrophotometrically.
Reverse transcription and cRNA synthesis as well as
labeling and hybridization were performed as recom-
mended by the manufacturer (Affymetrix, USA). Gene
expression profiling was performed using arrays of
Rat230_2 -type from Affymetrix. A Custom CDF Ver-
sion 11 with Entrez based gene definitions was used to
annotate the arrays. The Raw fluorescence intensity
values were normalized applying quantile normalization.
Statistical analysis
All statistical analyses with the exception of the micro-
arrays were performed using the SPSS statistical soft-
ware package. Comparisons between multiple groups
were performed using single-factor ANOVA, and sec-
ondary comparisons were performed using the Tukey
test.
Differential gene expression was analysed based on
log-linear mixed model ANOVA [30,31], using a com-
mercial software package SAS JMP7 Genomics, version
3.1, from SAS (SAS Institute, USA). A false positive rate
of a = 0.05 with Holm correction was taken as the level
of significance. The over-representation analysis (ORA)
is a microarray data analysis that uses predefined gene
sets to identify a significant over-representation of genes
in data sets [32,33]. Pathways belonging to various cell
functions such as cell cycle or apoptosis were obtained
from public external databases (KEGG, http://www.gen-
ome.jp/kegg/). A Fisher’s exact test was performed to
detect the significantly regulated pathways. The raw and
normalized data are deposited in the Gene Expression
Omnibus database http://www.ncbi.nlm.nih.gov/geo with
accession number GSE19460.
Results
Expression of truncated polycystin-2 leads to cyst
formation in the PKD2 (1-703) rat at postnatal
day zero (0)
We set out to investigate the early events that contri-
bute to cyst initiation and formation in polycystic
kidney disease, by using a previously described trans-
genic PKD2 (1-703) rat model that expresses a trun-
cated form of the PKD2 protein, which lacks almost the
entire C-terminal region [28]. This model develops
fibrosis and shows focal cyst formation, similar to
human ADPKD [28]. Although the exact mechanism of
pathogenesis in this model is not clear, it is possible
that truncated polycystin-2 exerts its effect through a
dominant negative mechanism by dimerization of the
N-terminal domain [34].
Animals from each of seven different ages (0, 6, 12,
24, 36, 48 and 60 days after birth) were obtained and
their kidney function was analysed. As demonstrated in
figure 1A and 1B both total kidney weight and the kid-
ney to body weight ratio were perceptibly higher in
mutant compared to wild type rats at all time points,
however the differences were not statistically significant
(Figure 1A and 1B). As expected, serum levels of K+,
Na+ and Ca2+ were comparable among mutant and
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Figure 1 Renal health evaluation of PKD2 mutant rats at different time points after birth. (A) Total kidney weight (g) of three wild-type
(SD) and three mutant rats (PKD2 Mut) for each time-point (0-60 days after birth). Values are means of total kidney weight +/- SE. (B) Kidney to
body weight ratio (%) of three wild-type (SD) and three mutant rats (PKD2 Mut) for each time-point (0, 12, 24, 36, 48 and 60 days after birth).
Values represent the mean of total kidney weight +/- SE, * indicates statistical significance at p < 0.05. (C) Serum urea levels (mg/dl) of three
wild-type (SD) and three mutant rats (PKD2 Mut) for each time-point (0-60 days after birth). Serum urea levels could not be determined at 0
days for either SD or PKD2 Mut rats (ND). Values are means of total kidney weight +/- SE. (D) Serum creatinine levels (mg/dl) of three wild-type
(SD) and three mutant rats (PKD2 Mut) for each time-point (0, 12, 24, 36, 48 and 60 days after birth). Serum creatinine levels could not be
determined at 0 days for either SD or PKD2 Mut rats (ND). Values represent the mean of total kidney weight +/- SE.
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wild-type animals (data not shown). On the other hand,
serum urea and creatinine values were higher only in
the 60 day old mutant rats (Figures 1C and 1D)
although these differences were not statistically signifi-
cant probably due to the low number of animals used.
Collectively, these results demonstrate normal renal
function at young age that begins to deteriorate at a
later stage.
In order to assess the cystic burden in these rats, cyst
grading was performed in H&E-stained kidney sections
from three wild-type and three PKD2 (1-703) rats (see
Materials and Methods for cyst grading). In the kidney
sections of the PKD2 (1-703) rats (no cysts were
detected in wild-type rats), cysts were visible as early as
0 days in the renal cortex, which indicates that cysto-
genesis begins in utero. Cysts seem to form and grow
from day 0 to day 24, where grading seems to plateau
(Figure 2B). A representative H&E-stained kidney sec-
tion from PKD2 (1-703) rats of different ages is depicted
on Figure 2A. Renal fibrosis was also graded in Azan-
stained kidney sections of PKD2 (1-703) rats at different
ages. As expected, fibrosis in the cortex clearly increases
with increasing age demonstrating a gradual destruction
of the renal parenchyma (Figure 2C).
Proliferation-related genes become deregulated at later
stages of cystogenesis
Cysts were demonstrated to appear at birth (0-day old
rats), and therefore the question arose as to which
genetic factors were involved at these initial stages of cyst
formation. Consequently, our investigation included gene
expression profiling of whole kidney homogenates, per-
formed at early stages of the disease, in PKD2 (1-703)
rats at 0, 6 and 24 days. Hence, three WT SD and three
PKD2 (1-703) male rats at the age of 0, 6 and 24 days
were sacrificed, their kidneys excised and RNA isolated
from whole kidney homogenates. Differentially expressed
genes were identified by microarray analysis using the
Affymetrix GeneChip® Rat Expression Array Rae230_2.
The microarray data revealed a total of 1011 statistically
significant differentially expressed genes at all three time
points (p-value ≤ 10-5.83) between mutant and wild type
rats. From those 39 genes were differentially expressed at
0 days. At 6 days there were 249 genes and at 24 days,
763 genes differentially expressed (data not shown).
Interestingly, none of the genes deregulated at day 0
were proliferation or cell-cycle related (Figure 3A). At
day 6 only two genes involved in cell cycle regulation,
namely ANAPC4 (p-value: 10-7,15) and CCND1 (p-value:
10-5,96), were found to be significantly downregulated in
mutant animals (Figure 3B and suppl. Table 1). On the
other hand, five cell-cycle related genes appear to be
up-regulated in mutant animals 24 days after birth (Fig-
ure 3C and suppl. Table 1). Most importantly, known
proliferation genes such as c-Myc were augmented in
the kidneys of mutant rats 24 days after birth (suppl.
Table 1) at the time point where cystic burden seems to
plateau (Figure 2B). In order to verify the microarray
results, the expression of classical proliferation cell-
cycle-related markers such as PCNA, c-Myc and Ki-67
was validated by quantitative real-time PCR analysis at
selected time points (0 and 24 days after birth). Consis-
tently, PCNA and Ki-67 mRNA levels were similar
among wild-type and mutant rats at both time points
(Figure 4A and 4B). In agreement with the microarray
results, c-Myc mRNA appears to be significantly upre-
gulated in mutant rat kidneys only at 24 days after birth
(Figure 4C). However, PCNA and c-Myc protein levels
were comparable among the two different groups at 0,
6, 12 and 24 days as judged by western blot analysis
(Figure 5). In order to verify these results we performed
Ki-67 staining on kidney sections from 0 days old SD
and Pkd2 mutant rats. As shown on Figure 6 the num-
ber of Ki-67 positive cells in renal tubules was similar
between wild-type and mutant animals. Collectively,
these results demonstrate that there is no statistically
significant difference in the proliferation between the
two groups. These results suggest that although renal
cysts appear at birth, proliferation abnormalities in Pkd2
transgenic rats are not evident at these early time points
but instead they might contribute to the PKD phenotype
at later stages of the disease.
A question still remains on which factors are involved
in early stages of cystogenesis. Pathway analysis demon-
strated a total of 42 pathways to be significantly deregu-
lated at all three time points, out of which only one (the
renin-angiotensin system) was deregulated at 0 days
(p-value: 0,047; Figure 7A), 6 pathways become deregu-
lated at 6 days (Figure 7B) and 35 pathways become
deregulated at 24 days (Figure 7C). The six pathways
deregulated at the time point of 6 days are the focal
adhesion pathway (p-value: 0,027), the Wnt pathway
(p-value: 0,048), glutathione metabolism (p-value: 0,021),
basal transcription factors (p-value: 0,035), chronic
myeloid leukemia (p-value: 0,044) and metabolism of
xenobiotics by cytochrome P450 (p-value: 0,019). Inter-
estingly, the cell cycle pathway which is represented by
63 genes on the Affymetrix chip is not significantly
deregulated in any of the three time points examined
(p-values: 1; 0,472204 and 0,22454 at 0, 6 and 24 days,
respectively). Other proliferation-related pathways
including the JAK-STAT pathway and the MAPK path-
way become deregulated at the time point of 24 days
(p-values: 0,009 and 1,7 × 10-5 respectively). Figure 7
summarizes the significantly deregulated pathways
found after analysis with Fischer’s exact test. The list of
all the significant genes of the above pathways is shown
in Additional file 1: tables s2, s3, s4, s5, s6 & s7.
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Figure 2 Cyst and fibrosis grading of PKD2 mutant rats at different time points after birth. (A) Images for different cyst grading from 0-60
day old male PKD (1-703) rats. Cyst grades range from 1.5 at 0 days old rats to 4 in 60 days old rats. (B) Cyst grading from three PKD2 mutant
rats was determined using the criteria described in the Materials and Methods for each time point (0, 6, 12, 24, 36, 48 and 60 days after birth).
Values represent the mean of total kidney weight +/- SE. (C) Fibrosis grading from three PKD2 mutant rats was determined using the criteria
described in the Materials and Methods for each time point (0, 6, 12, 24, 36, 48 and 60 days after birth). Values represent the mean of total
kidney weight +/- SE. Fibrosis grade at day 0 could not be determined (ND).
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Discussion
One of the primary events of cyst formation in ADPKD
is believed to be the increased proliferation of tubular
epithelial cells and much of the research in the field has
focused on identifying the molecules that contribute to
this. Consequently many of the therapeutic strategies in
PKD target this abnormal cellular proliferation
[16,17,21,22,35-38]. Most studies of human and rodent
PKD, however, have unavoidably utilised kidneys
obtained at a later stage of the disease, at a stage where
chronic or end-stage renal failure has already begun.
Research has focused on cysts that are in the continued
growth and expansion phase rather than cyst initiation
[9,10,39]. This might have given rise to a false represen-
tation of the factors affecting the progression of the dis-
ease, since chronic secondary effects of renal failure
might have superimposed the primary defects in the
initiation and progression of PKD. Therefore, the char-
acterisation of the detailed molecular cues at the very
early stages of initiation of cystogenesis remain
unknown and in need of intensive investigation.
In this study, we attempted to identify the contribu-
tion of proliferation abnormalities to cystogenesis by uti-
lising a transgenic rat model overexpressing a truncated
form of PC-2. As demonstrated in the gene expression
profiling of the 0, 6, and 24 days-old PKD2 (1-703) rats,
proliferation-related pathways become deregulated at 24
days as compared to their normal counterparts. Interest-
ingly, the cell cycle pathway represented by 63 genes on
the microarray did not significantly change at any of the
three time points examined. Cyst grading performed at
these time points, showed that cysts are visible as early
as 0 days and cyst formation proceeds up to and reaches
a maximum at 24 days. Cyst grading highlights the fact
that initial cyst formation may take place in utero during
embryonic development and cysts grow in size as the
animal grows older. Similarly, a gradual progression in
fibrosis was observed with increasing age in the affected
rats. Not surprisingly, deterioration of renal function
was not observed in the 60 days period as judged by
various serum parameters examined (Figure 1). This was
expected since PKD2 (1-703) rats display a marked dif-
ference in markers of renal function at much later stages
of the disease and renal insufficiency becomes apparent
at 15 months of age [40].
Quantitative Real-Time PCR analysis correlated with the
microarray data and showed that c-myc mRNA expression
was significantly higher in PKD2 (1-703) rats at 24 days
and PCNA and Ki67 mRNA levels practically remain
unchanged, with no significant difference between the
PKD2 (1-703) and WT rats. Similarly, protein levels of c-
Myc and PCNA did not show any difference in the two
groups at early time points. In agreement to this,
immuno-histochemical staining with Ki-67 confirmed that
there is no difference in proliferation between the two
groups (Figure 6). As expected, PCNA protein levels
decrease in both WT and mutant rats at 24 days demon-
strating a reduction in cellular proliferation in the kidney.
These results demonstrated that proliferation-related
genes remained unaffected at the early time points of
cyst formation in the PKD2 (1-703) rat. Supporting data
for this were observed by Piontek et al. who have
demonstrated that cellular proliferation was not
increased in cystic specimens compared to age-matched
Figure 3 Volcano plots of cell cycle and proliferation-related genes. Volcano plots of cell cycle and proliferation-related genes analysed by
microarray experiments of whole kidney homogenates of PKD2 (1-703) rats (Mut) compared to Wild type SD rats (SD) in the time points of 0
days (A), 6 days (B) and 24 days (C). Each data point represents a different gene. Data points to the right of the Y-axis denote up-regulation of
the gene, whereas data points to the left of the Y-axis denote down-regulation. Some of the significantly deregulated genes’ names are shown.
The dotted red line represents the threshold of the p-value: 10-5.83 (Bonferroni correction).
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controls in a mouse model with inactivation of the
Pkd1. The authors suggested that defective growth regu-
lation could not be the primary defect in the initiation
of cysts, but rather the relationship between prolifera-
tion and cyst formation might be indirect. They also sta-
ted, that proliferation might occur in bursts, and implied
that other studies that have implicated proliferation as a
primary cause of polycystic kidney disease might have
acquired proliferation data from cysts undergoing bursts
of proliferation [41]. More supporting data were pro-
vided by a mouse model of kidney-specific inactivation
of Kif3a which resulted in the loss of primary cilia, in
which the rate of cell proliferation in pre-cystic tubules
in mutant mice was similar to the rates in control litter-
mates. These results demonstrated that the loss of pri-
mary cilia did not stimulate cell proliferation, but rather
caused abnormalities in the orientation of cell division
due to abnormal planar cell polarity (PCP) [42]. Simi-
larly, a recent study in which a Pkd1-inducible mouse
model was treated with the nephrotoxicant DCVC after
Pkd1-gene inactivation showed that unrestricted cellular
proliferation after injury is not the underlying mechan-
ism for cyst formation. The authors suggested that other
factors such as aberrant PCP and increased canonical
Wnt signalling may be involved in this process [43]. On
the contrary, other reports conclude that proliferation
might be an early event preceding cyst formation
[44,45]. These discrepancies may be attributed to the
difference in age of the experimental animal models
used in the respective studies.
Although unrestricted cellular proliferation may not to
be involved in initial cyst formation, our data suggest
that alternative mechanisms might be involved in this
process. The renin-angiotensin system (RAS), focal
adhesion pathways, the Wnt signaling pathway, glu-
tathione metabolism, basal transcription factors, chronic
myeloid leukemia pathway and the metabolism of xeno-
biotics by cytochrome P450 appear to be affected at
very early time-points (0 and 6 days) correlating with
the initial appearance of cysts.
The RAS failure is of considerable interest. It is known
that the RAS controls the proper development of the kid-
ney, although the exact mechanisms are poorly under-
stood. It is suggested that RAS can regulate ureteric bud
morphogenesis by affecting the expression of various
growth factors in the metanephric mesenchyme[46]. The
genes that contribute to the statistically significant dereg-
ulation of the RAS are chymase 1 (CMA1), carboxypepti-
dase A3 (CPA3) both of which are secreted by mast cells,
and Leucyl/cystinyl aminopeptidase also known as insu-
lin-responsive aminopeptidase and angiotensin IV recep-
tor (LNPEP/IRAP/AT4R). All three of them were shown
to be downregulated in PKD2 (1-703) compared to WT
SD rats at the time point of 0 days. Chymase is an
Figure 4 Quantitative PCR analysis of selected proliferation-
related genes. Relative amount of mRNA of PCNA (A), Ki67 (B) and
c-myc (C) as analysed by quantitative PCR analysis of whole kidney
homogenates of PKD2 (1-703) rats (Mut) compared to wild type SD
(SD) rats in the time points of 0, 6 and 24 days. Data represent the
mean of normalised fold change from three independent samples
± SEM (p < 0.01, *: significant difference). Data were normalised
against GAPDH.
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Figure 5 Western blot analysis of selected proliferation-related genes. Relative amount of c-myc (A) and (PCNA) protein in whole kidney
homogenates of PKD2 (1-703) rats (Mut) compared to wild type SD (SD) rats in the time points of 0, 6, 12 and 24 days. Protein levels are
represented as the mean of normalised fold change of two independent Western blotting experiments ± SEM. Data were normalised against
b-actin expression.
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Figure 6 Immuno-histochemical staining of Ki-67 on kidney sections of 0 days old SD and PKD2 mutant rats. (A) Images of a
representative kidney section of 0 days old SD and PKD2 mutant rats stained with Ki-67 under 400× magnification. (B) Average number of Ki-67
stained nuclei per visual field in three SD (Nr. 34, 35 and 36) and three PKD2 mutant (Nr. 30, 31 and 32) rats. Data represent the mean ± SEM of
Ki-67 positive cells in five different visual fields.
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enzyme capable of efficient conversion of Ang I to Ang
II, providing an ACE-independent mechanism of Ang II
production. It is known than in humans and other pri-
mates, 50%-70% of Ang II produced is chymase-depen-
dent [47]. In ADPKD chymase activity was detected in 13
of 14 tissue extracts from ADPKD patients suggesting
the presence of an alternative mechanism for Ang II gen-
eration in this disorder [48]. Despite that, the significance
of chymase 1 downregulation in kidney extracts from 0
days PKD2 (1-703) rats is unknown.
IRAP/angiotensin IV receptor is expressed at high
levels in the proximal tubules of rat kidneys [49].
Increased levels of angiotensin IV in animal models
results in augmentation of renal cortical blood flow and
urinary sodium excretion, something that can be poten-
tially reverted in our 0 days mutant rats by downregula-
tion of IRAP [50]. In cell lines, angiotensin IV interferes
with the focal adhesion complex by causing a rapid
phosphorylation of p125-focal adhesion kinase and p-68
paxillin [51]. This observation is of considerable interest
since we observed deregulation of the focal adhesion
pathways at 6 days old PKD2 (1-703) rats.
As mentioned above, the gene expression profile data
demonstrate that the RAS pathway is the only pathway
deregulated at day 0. This malfunction may influence
the development of the renal nephron by interfering
with various pathways involved in kidney development.
It should be noted that kidney development in the rat
proceeds until postnatal day 7 [52]. RAS orchestrates a
complicated process during nephron development in the
metanephric mesenchyme by regulating expression of
various growth factors including many Wnt signaling
members such as Wnt9b and Wnt11[53]. At the same
time it can interfere with focal adhesion integrity in tub-
ular epithelial cells by altering the phosphorylation of
focal adhesion proteins. As a result it is possible that an
imbalance in the RAS system during early kidney devel-
opment can initiate a chain of events which may include
Wnt and focal adhesion pathways, thereby resulting in
cyst formation (Fig 8, hypothetical model). Our data
demonstrate that deregulation of Wnt and focal adhe-
sion pathways are detected at postnatal day 6 following
failure of the RAS pathway at postnatal day 0.
Conclusions
In conclusion, we demonstrated that aberrant cellular pro-
liferation is not involved in the initial stages of cyst forma-
tion, in the rat model under study, as cyst formation
seems to precede deregulation of proliferation-related
pathways. Nonetheless, epithelial cell proliferation seems
to be an important determinant of cyst expansion. As far
as therapy is concerned, considering cyst formation as a
Figure 7 Graphical overview of the significantly regulated pathways. Graphical overview of the significantly regulated pathways analysed
by Fischer’s exact test (log10 of the p-value is represented) in the gene expression profiling of whole kidney homogenates of PKD2 (1-703) rats
at the ages of 0, 6 and 24 days.
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multistep process, perhaps a dual strategy for therapeutic
intervention could be employed. One branch could be to
target cyst initiation, which would decrease the number of
cysts formed at an early age and a second branch to target
the process of cyst expansion, and specifically the mechan-
isms of proliferation and fluid secretion. As more is
learned regarding the normal functions of polycystins and
how mutations in them disrupt normal cell physiology, the
ability to design therapeutic interventions based on gene
function and specific pathophysiological mechanisms may
progress.
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